UNLIMITED TURBO LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 17:30:01 04/06/2024 BST | ||
| 3.76 EUR | +5.03% |
|
| Current month | +6.46% | ||
| 1 month | +45.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 3.76 | +5.03% |
| 03/06/24 | 3.58 | +0.56% |
| 31/05/24 | 3.56 | +1.71% |
| 30/05/24 | 3.5 | +2.04% |
| 29/05/24 | 3.43 | -1.72% |
Real-time Euronext Paris
Last update June 04, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| QS4NB | |
| ISIN | NLBNPNL2O268 |
| Date issued | 26/02/2024 |
| Strike | 683.2 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.82 € |
|---|---|
| Lowest since issue | 2.15 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.3
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- QS4NB Certificat
